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Summary Due to the increasing therapeutic use of iummunoregulatory agents and the potential effects on
cellular function, we examined the modulation of in vitro beta2-microglobulin (02m) production rates by
'normal' tonsil and leukaemic B-cells in response to a number of these agents. Tonsil B-cells responded to
phorbol ester (TPA) by an increased A2m production rate, which was further enhanced by the combined
stimuli of TPA plus the calcium iorophore A23187. In marked contrast, however, lymphocytes from a
majority (8/11) of B-cell malignancies showed a suppression of the TPA-induced P2m production rate in
response to the combined TPA/A23187 stimulus. These different responses of 'normal' and malignant B-cells
were not apparent when IgM production rates. were examinedL The recombi-nant cytokines IL-1, IL-2, IFN-a,
IFN-y and TNF also enhanced f2m production rates of both normal and leukaemic B-cells, but to a
considerably lesser exten-t than did TPA. Bryostatin-I increasd Jbm production to a level intermediate
between that obtained by TPA and the cytokines. It is sgge that 2m production rates may correspond to
the degree of B-cell differentiation, and/or to the degree cclurr 'activation'. The results further indicate
that the in vitro measurement ofP2m prdution provide a different index of the cellular response than that
obtained by the conventional measurement of EgM productin.
The 12 kDa beta2-microglobulin (p2m) molecule is expressed
in non-covalent association with the MHC Class I (HLA-
ABC) glycoprotein heavy chain (Peterson et al., 1974) on the
surface of most nucleated cells (Daar et al., 1984). In addi-
tion to its release during cell membrane turnover, which
occurs following internalisation of the HLA heavy chain
(Cresswell et al., 1974), 1n2m levels in the extracellular com-
partment may additionally result from direct cellular secre-
tion (Nilsson et at., 1974; Conway & Poulik, 1976). In broad
terms, serum P2m concentrations have been shown to be of
prognostic value in B-CLL and myelomatosis, apparently
reflecting tumour cell mass (Norfolk et al., 1979; Simonsson
et al., 1980; Spati et al., 1980; Child & Kushwaha, 1984;
Bataille & Grenier, 1987). This is particularly striking in
myelomatosis where serum P2m can be used in the
stratification and monitoring of disease. A progressive rise in
serum P2m appears to accompany the onset of active disease
in B-CLL (Simonsson et al., 1980), and is paralleled by a
greater in vitro P2m production rate by the leukaemic B-cells
from active disease (Simonsson et al., 1986; Totterman et al.,
1986). The tumour itself is thus implicated as the source of
increasing serum P2m, but since elevated levels are also
observed in inflammatory and viral conditions (Plesner,
1980), it is conceivable that these increased levels may in part
be due to an immunological response to the malignancy.
Various immunoregulatory agents are known to influence
lymphoid cell differentiation, often with corresponding
stimulation of P2m production. Recent therapeutic advances
have been noted in the treatment of conditions such as hairy
cell leukaemia (HCL) by a-interferon (IFN-a) (Quesada et
al., 1986; Genot et al., 1987), a lymphokine which amongst
others is known to increase the expression of cell-membrane
02m-associated determinants in vitro (Wallach et al., 1982).
However, as relatively little is known about the in vitro
response of leukaemic cells to these agents with respect to
P2m production, we compared the inductive capacity of eight
different immunoregulatory agents on the P2m production
rates of both non-malignant tonsil and leukaemic B-cells.
Nisteri and
Source andpreparation ofB-cellfractions
Non-malignant human B-cells Human non-malignant B-cells
were obtained from four separate tonsils which were removed
during routine tonsillectomy. After teasing of the tissue with
scalpel and forceps, mononucler tonsil cells were isolated by
Ficoll-Hypaque density gradient centrifugation (1.077 g ml-';
Lymphoprep, Nycomed, UK). Monocytes/macrophages were
depleted by adherence to plastic Petri dishes (Nunc, Gibco)
for 90min at 37C. The lymphocyte-rich non-adherent frac-
tion was then T-cell depleted using a standard sheep erythro-
cyte rosetting technique whereby non-rosetting B-cells were
obtained from the interface of a subsequent Ficoll gradient.
The resulting tonsil lymphoid population comprised 0-1%
monocytes (CD14 +), 1-2% T-cells (CD2 +, CD5 +), and
exceeded 90% B-cells as defined by expression of CD19,
CD20 and CD21.
Leukaemic B-cells Leukaemic cells from a total of 11 cases
(clinical and haematological data detailed in Table I) were
examined in this study. These were diagnostically classified as
chronic lymphocytic leukaemia (B-CLL; n = 3), 'prolympho-
cytoid variants' of B-CLL (CLL-Pro; n = 5), non-Hodgkin's
lymphoma (B-NHL; n = 1), prolymphocytic leukaemia (B-
PLL; n = 1) and hairy cell leukaemia-proliferative variant
(HCL-v; n = 1) on the basis of morphological appearances
and immunophenotypic profiles as previously described
(Melo et al., 1986; Drexler & Scott, 1989). Mononuclear
leukaemic cells were purified by density gradient centrifuga-
tion of heparinised blood on Ficoll-Hypaque and the
harvested cells were examined immediately for the expression
of lymphoid-associated membrane determinants by indirect
immunofluorescence in suspension using a microtitre plate
technique (Campana & Janossy, 1986). Immunophenotyping
reagents included polyclonal goat anti-human immuno-
globulin heavy- and light-chain antibodies, and a wide range
of murine anti-human monoclonal antibodies (Table II).
Culture conditions
Fractionated tonsil and leukaemic B-cells were cultured for
up to 10 days in RPMI 1640 medium (Gibco) supplemented
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Table I Diagnostic classification, and clinical and haematological data ofpatients with B-cell malignancies
examined in this study
Patient Diagnosisa Age Sex WBC (x 109 1') Treatmentb % PLC
SE CLL 70 M 42 C+P <10
NL CLL 66 F 114 none <10
AA CLL 62 M 95 none <10
JF CLL-Pro 70 M 56 none 12
EP CLL-Pro 72 M 460 C 22
PR CLL-Pro 59 F 75 none 17
KH CLL-Pro 57 M 90 none 16
MP CLL-Pro 74 F 142 none 20
KT PLL 61 M 144 none 89
RT NHL 68 M 90 none n.a.
LM HCL-vd 68 F 400 IFN-a n.a.
aSee Materials and methods for diagnostic criteria. bC, chlorambucil; P, prednisolone. cPercentages of
morphologically assessed prolymphocytoid cells (PLC); n.a. not applicable. B-CLL, < 10% PLC; CLL-Pro,
11-55% PLC; B-PLL, >55% PLC (Melo et al., 1986). dProliferative variant of hairy cell leukaemia;
morphological and immunophenotypic features of HCI but in which functional studies were more in
keeping with B-PLL (Scott et al., 1990).
Table II Immunological reagents used in this study for
characterisation of normal tonsil and leukaemic B-cells
Cluster Principal
designation' reactivity Antibody Sourceb
Monoclonal antibodies
CD2 T-cells RFT- I1 RFH
CD5 T-cells (B-CLL) RFT-1 RFH
CD6 T-cells (B-CLL) RFT-12 RFH
CDIO Pre-B cells (CALLA) RFAL-13 RFH
CD14 Monocytes VIM-13 Dr Knapp
CD15 Monomyeloid cells VIM-D5 Dr Knapp
CD19 B-cells RFB-9 RFH
CD20 B-cells RFB-7 RFH
CD21 B-cells RFB-6 RFH
CD22 B-cells RFB-4 RFH
CD25 IL-2 receptor TAC Dr Waldmann
CD38 Plasma cells OKT-10 Ortho
HLA-DR B-cells/monocytes RFDR-2 RFH
- 'Late' B-cells FMC7 Dr Zola
- 'Activated' B-cells UCHBI Dr Armitage
- 'Activated' B-cells B5 Dr Freeman
- 'Activated' B-cells B7 Dr Feeman
Polyclonal antibodies
anti-kappa SBA
anti-lambda SBA
anti-IgM SBA
'Cluster designations as defined by the four International
Workshops. "Antibody sources: RFH, Royal Free Hospital, London;
Ortho, Ortho Diagnostics; SBA, Southern Biotechnology Assoc,
Birmingham, AL, USA; Dr Knapp, Vienna, Austria; Dr Waldmann,
Bethesda, MD, USA; Dr Zola, Bedford Park, Australia; Dr
Armitage, London, UK; Dr Freeman, Boston, MA, USA.
within penicillin (100Umlm'), streptomycin (100pgmlg')
and 10% (v/v) heat-inactivated fetal calf serum (Sera-Lab) at
37°C in a humidified 5% CO2 atmosphere. Cells (0.4 x 106)
were resuspended in 200 AI complete medium in flat-
bottomed 96-well culture plates (Nunc, Gibco) without fur-
ther addition or exchange of the culture medium. Inducing
reagents at predetermined standard concentrations, or in
graded doses, were added at the initiation of the cultures and
sufficient replicate wells were established to permit termina-
tion ofcultures and removal of 100p1 cell-free supernatant at
24 h intervals.
Inducers used
Recombinant (r) cytokines used in this study included: rTNF
(tumour necrosis factor; Knoll AG, BASF, Ludwigshafen,
FR Germany), rIFN-y, IL-1 and IL-2 (y-interferon and
interleukins I and 2; Biogen, Geneva, Switzerland) and
rIFN-x (Kirby, Warwick, UK). The specific activity of rTNF
was 6.63 x 106 U mg-' protein, of IFN-a 2.5 x 106 U mg-'
protein, of IFN-y 3.3 x IO' Umg-' protein, of IL-1
5 x IO' U mg-' protein, and of IL-2 1.7 x 106 U mg-' pro-
tein. These cytokines were stored frozen and diluted prior to
use in RPMI 1640 medium. Other inducers examined
included: bryostatin-1, which was extracted from the marine
bryozoan Bugula neritina; TPA (12-O-tetradecanoylphorbol
13-acetate; Sigma); and the calcium ionophore A23187
(Sigma). Bryostatin-1, TPA and A23187 were dissolved in
DMSO at 103 M, stored frozen and then further diluted to
final concentrations in culture medium.
Analysis ofbeta2-microglobulin (i2m) secretion
In vitro P2m production was determined by radioimmuno-
assay of cell-culture supernate samples, taken on successive
days from cultures maintained at 2 x 106cells ml-' for up to
10 days. Mean rates of synthesis (ng ml-' (106cells)-' day ')
were calculated over the observed period of linear produc-
tion, normally between days 2 and 6. Supernate P2m concen-
trations were measured using a modification of a previously
described method (Swanson et al., 1982). Briefly, monoclonal
anti-A,m antibody L368 (American Type Culture Collection),
which was purified from hybridoma culture. medium by
Protein-A chromatography, was incubated with 100,lO of
1:10 tonsil or leukaemic B-cell culture supernate and a stan-
dard amount of 125I-labelled soluble P2m. Following overnight
incubation at 4°C and precipitation of immune complexes
with 18% polyethylene glycol (PEG), the amount of
precipitated activity was measured and the culture supernate
P2m concentration thus calculated. Three internal P2m stan-
dard preparations, representing low (4.3 ngml-'), mid-range
(37.5 ngml-') and high (99.9 ngml-') ligand concentrations,
gave inter-assay variation coefficients (CV) of 16.3%, 6.7%
and 6.5% respectively (n = 23). Intra-assay reproducibility,
determined by replicate measurement of a single sample
(mean 30.7 ngml-'; n = 10), was 4.5%.
Analysis ofimmunoglobulin production
Immunogobulin production by cultured B-cells was measured
using a specific ELISA as described in detail previously
(Drexler et al., 1988).
Results
B2m production rates were determined in three cases of B-
CLL, five cases of CLL-Pro, one case each of B-NHL,
B-PLL and HCL-v and four (T-cell depleted) tonsil B-cell
fractions cultured with one of eight mitogenic or
immunoregulatory agents, or combination thereof. Pheno-P2m PRODUCTION BY NORMAL AND MALIGNANT B-CELLS 677
typic characteristics of the tonsil and leukaemic B-cells
examined in this investigation are summarised in Table III.
In all cases of B-cell malignancy, T-cell associated CD2 and
monocyte associated CD14 determinants comprised less than
5% of the mononuclear fraction tested, with the exception of
the B-NHL case (RT) which had 11% CD2+ cells. Normal
tonsil B-cell fractions contained <1% CD14+ and 1-2%
CD2+ components. Cell viabilities were assessed by tryphan
blue exclusion on a daily basis throughout the culture period,
and although a slow decline was noted for the control cul-
tures, viabilities for all treatments generally remained in
excess of 60% at day 5. It was apparent using duplicate
cultures that reduced viability was associated with a corre-
spondingly reduced supernate P2m concentration, which sug-
gests that cell death does not significantly contribute to
supernate P2m levels. In addition, as,2m production rates
were calculated over the linear phase of P2m release, any
significant effect on the P2m production rate due to declining
viabilities would thus be excluded from the calculation.
Dose-response ofnormal and malignant B-cells to TPA
The effect of serial concentrations of the phorbol ester TPA
can be seen from Figure 1. TPA in concentrations below
10' M were largely ineffective in stimulating P2m production
above that of the control value, for both tonsil (n = 2) and
leukaemic (n = 4) B-cells. An apparent difference in the
threshold of response to TPA can be observed between tonsil
and leukaemic B-cells, since three of the four cases of B-CLL
examined showed an increase in P2m secretion, compared to
spontaneous production, at a TPA concentration of 10-9 M.
In contrast, both of the tonsil B-cell fractions studied only
showed a clear response to TPA at 10-8 M, suggesting that
B-CLL cells may be slightly more sensitive to TPA than
tonsil B-cells.
12m production by normal and malignant B-cells; effects of
TPA, the calcium ionophore A23187 and bryostatin-l
The P2m production rates of tonsil and leukaemic B-cells
cultured with TPA, A23187 and bryostatin-l either alone or
in combination are shown in Table IV.
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Figure I Dose-response curve ofP2m production in the presence
of increasing TPA concentrations (10-" to 10-6M). Results are
shown as the mean P2m production rates (ng(106cells)f1ml-'
day-') for two normal tonsil B-cell fractions (open circles: curves a
and b) and four malignant CLL-Pro B-cell fractions (filled circles:
curves c-f). C indicates the spontaneous (control) P2m production
obtained in the absence of TPA.
Tonsil B-cells The mean unstimulated (control or spon-
taneous) P2m production by tonsil B-cells (n
= 4) was 13.4
(range 10.8-14.6) ngml-' (106cells)-' day-', while that of
TPA-treated tonsil B-cells was 50.9 (range 41.3-69.4). The
P2m production rate in the presence of TPA alone was,
however, less than that obtained when TPA was sup-
plemented with the calcium ionophore A23187; this combina-
tion increased additively the mean P2m production rate to
71.2 (range 62.7-78.4) ngml-' (106cells)-' day-'.
Malignant B-cells The mean unstimulated P2m production
by leukaemic B-CLL/CLL-Pro cells (n = 8) was 14.3 (range
6.9-23.1) ngml-' (106cells)-' day-', with a considerably
higher spontaneous level of secretion observed for the non-
CLL (B-NHL, B-PLL and HCL-v) cases (mean 30.9, range
Table III Immunophenotypic characteristics of enriched normal tonsil B-cells and leukaemic B-cells examined in this studya
Tonsils B-CLL CLL-Pro B-NHL B-PLL HCL-v
I II III IV SE EP PR EP PR MP KH JF RT KT LM
Surface Ig
kappa n.t. n.t. n.t. n.t. <5 <5 51 <5 95 <5 <5 <5 88 <5 <5
lambda n.t. n.t. n.t. n.t. <5 37 <5 <5 <5 <5 <5 93 <5 92 57
IgM n.t. n.t. n.t. n.t. <5 37 29 52 95 <5 <5 80 95 88 <5
B-CLL associated markers
CD5 <5 <5 <5 <5 <5 97 97 80 95 73 86 95 12 93 <5
CD6 n.t. n.t. n.t. n.t. n.t. 98 94 90 92 <5 65 83 6 94 <5
CD1O n.t. n.t. n.t. n.t. n.t. <5 <5 <5 <5 <5 <5 <5 <5 <5 <5
CD19 82 57 86 88 96 96 88 97 91 95 82 93 80 95 78
CD20 74 67 78 86 94 98 92 95 97 94 87 92 78 93 77
CD21 61 47 73 85 <5 95 61 95 94 <5 55 87 77 88 <5
CD22 n.t. n.t. n.t. n.t. <5 <5 <5 75 94 69 <5 92 70 88 74
HLA-DR n.t. n.t. n.t. n.t. <5 95 88 96 97 90 93 95 82 95 91
B-activation markers
FMC7 n.t. n.t. n.t. n.t. 85 22 13 23 72 18 28 5 76 95 87
UCHBI n.t. n.t. n.t. n.t. n.t. <5 <5 <5 <5 <5 5 <5 83 74 <5
B5 n.t. n.t. n.t. n.t. n.t. 98 90 <5 95 92 85 90 71 93 62
B7 n.t. n.t. n.t. n.t. n.t. <5 <5 <5 <5 <5 <5 <5 <5 <5 <5
CD25 n.t. n.t. n.t. n.t. n.t. <5 <5 90 <5 <5 90 94 <5 87 5 CD38 n.t. n.t. n.t. n.t. <5 <5 <5 90 90 <5 <5 60 <5 95 <5
T and myeloid markers
CD2 <5 <5 <5 <5 <5 <5 <5 <5 <5 <5 6 <5 11 <5 <5
CD14 <5 <5 <5 <5 <5 <5 <5 <5 <5 <5 <5 <5 <5 <5 5
CD15 n.t. n.t. n.t. n.t. n.t. <5 <5 <5 <5 <5 <5 <5 <5 <5 7
aResults are shown as the percentages positive cells expressing any given determinant. Case groups: B-CLL, chronic lymphocytic leukaemia;
CLL-Pro, prolymphocytoid variant of B-CLL; B-NHL, non-Hodgkins lymphoma; B-PLL; prolymphocytic leukaemia; HCL-v, proliferative
variant of hairy cell leukaemia.
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Table IV P2m secretion rates by normal tonsil and leukamic B-cells in the presence of the protein kinase C activators TPA, calcium ionophore
A23187 and bryostatin-la
Controlb TPAc Bryo-ld A23187d TPAIA23187C Bryo-IIA23187'
Normal tonsils
I 14.1 44.4 (3.1)* n.t. 19.7 (1.4) 69.3 (4.9) 43.7 (3.1)
II 14.6 69.4 (4.7)* 35.0 (2.4) 27.7 (1.9) 78.4 (5.4) 73.0 (5.0)
III 14.2 41.3 (2.9)* 35.0 (2.5) 27.0 (1.9) 62.7 (4.4) 44.0 (3.1)
IV 10.8 48.7 (4-5)* 27.0 (2.5) 20.5 (1.9) 74.4 (6.9) 76.7 (7.1)
B-cell malignancies
CLL (SE) 6.9 29.7 (4.3)* 16.6 (2.4) 20.7 (3.0) 23.1 (3.3) n.t.
CLL (AA) 13.1 42.9 (3.3) 19.6 (1.5) 10.5 (0.8) 53.8 (4.1) 36.7 (2.8)
CLL (NL) 19.8 50.3 (5.0) n.t. n.t. 29.3 (2.7) n.t.
CLL-Pro (EP) 15.5 29.9 (1.9) 21.7 (1.4) 14.0 (0.9) 35.2 (2.3) n.t.
CLL-Pro (PR) 7.2 84.9 (>10) 24.5 (3.4) 6.5 (0.9) 60.8 (8.4) n.t.
CLL-Pro (MP) 18.3 60.0 (3.4) 29.3 (1.6) n.t. 28.3 (1.6) 40.3 (2.2)
CLL-Pro (KH) 23.1 102.5 (4.4) 39.3 (1.7) n.t. 67.7 (2.9) 73.9 (3.2)
CLL-Pro (JF) 19.8 50.3 (2.5) n.t. n.t. 81.2 (4.1) n.t.
NHL (RT) 37.8 151.0 (4.0) 83.2 (2.2) n.t. 141.9 (3.7) n.t.
PLL (KT) 25.8 76.5 (3.0) n.t. n.t. 65.5 (2.6) 77.4 (3.0)
HCLv (LM) 29.1 88.6 (3.0) 52.4 (1.8) n.t. 70.3 (2.4) n.t.
aResults are shown as absolute P2m production rates (ngml-' (106cells)' day 1) in the presence or absence (control) of inducers.
Production rate ratios, relative to the control (spontaneous) value, are shown in parentheses. bControl value indicates spontaneous P2m
production obtained in the absence of inducers. CTPA concentrations in culture for all cases investigated were either 10-8 or 2 x 10-8 M (*),
with the exception of CLL-Pro (KH) which was studied at 0-7 M. dBryostatin-I and the calcium ionophore A23187 used at final
concentrations of 10-8M respectively. 'Inducer combinations using the same concentrations of reagents as for single inducer studies.
25.8-37.8). TPA treatment induced mean P2m production rates
for B-CLL/CLL-Pro cells of 56.7 (range 29.7-84.9) ngml-'
(106cells)-' day-', compared to 105.3 (range 76.5-151.0) for
non-CLL cases. However, in contrast to tonsil B-cells, the
P2m production rates obtained with TPA in combination with
A23187 were lower in 8/11 cases of B-cell malignancy than
that observed for TPA alone; with mean production rates for
TPA plus A23187 being 47.4 (range 23.1-81.2) and 92.9
(range 66.6-141.9) ngml-' (106 cells)-' day-' for B-CLL/
CLL-Pro and non-CLL cases respectively.
Thus the response of tonsil and leukaemic B-cells to the
combined stimuli of TPA and A23187 differed. TPA-induced
P2m production was enhanced by A23187 in 4/4 tonsil B-cells
(mean increase relative to control from 3.8 to 5.3), but was
suppressed in 8/11 cases of B-cell malignancies examined
(mean decrease relative to control from 4.0 to 3.3 and from
3.4 to 3.0 for B-CLL and non-CLL cells respectively), as
illustrated in Figure 2.
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Figure 2 Relative p2m secretion rates obtained in the presence of
TPA alone or TPA plus calcium ionophore A23187. Results are
shown as ng (106cells)1 ml-' day-' P2m where the dotted line
indicates equivalent production rates. The four open circles repre-
sent data for normal tonsil B-cells and the filled circles are the
results for malignant B-cell fractions (a, B-CLL; b, CLL-Pro; c,
B-PLL; d, B-NHL; e, HCL-v).
Bryostatin-1 was a less potent inducer of P2m production
than TPA, but when used in conjunction with A23187, an
increased P2m production rate was observed for both tonsil
and leukaemic B-cells.
Correlation between P2m production and IgM secretion This
study also examined possible correlations between ,2m and
IgM secretion rates in nine cases of B-cell malignancy. The
mean spontaneous IgM production rates, determined over a
period of 5 days and expressed as jig ml1' (106 cells)-' day ',
for B-CLL (n = 3), CLL-Pro (n =4) and B-NHL/B-PLL
(n=2) cases were <0.01, 0.07 and O.lpgml-'
(106cells)-' day-' respectively, suggesting a common rela-
tionship between the levels of P2m and IgM production with
the stage of leukaemic B-cell differentiation (rs= 0.88;
P <0.05). However, in contrast to the broadly consistent
3.5-fold increase in P2m production induced by TPA, the rate
of IgM production increased by an approximate factor of 25
for the B-CLL cases, a mean factor of 14 for CLL-Pro cases
and only 5 for the B-NHL/B-PLL cases. Furthermore, when
TPA was supplemented with A23187, the rates of IgM prod-
uction for all cases examined were generally similar to that
observed with TPA alone, and in contrast to the suppressive
effect of A23187 on P2m production in TPA cultures.
P2mproduction by normal andmalignant B-cells; effects of
rIFN-y, rIFN-c rIL-1, rIL-2 and rTNF (Table V)
Of the five different cytokines studied, IFN-y induced a
greater increase in P2m production than did IFN-a, with
relative production rates compared to control levels of 1.9
(range 1.5-3.2; n = 11) and 1.5 (range 1.3-1.8; n =6)
respectively. Similarly, IL-2 induced P2m production to a
greater degree than IL-1, with factors of 1.7 (range 1.0-2.3;
n = 10) and 1.2 (range 0.9-1.7; n = 6) respectively. Culture
in the presence of TNF alone did not significantly increase
P2m production (1.1; range 0.9-1.2; n = 11) although TNF
and IFN-y in combination produced a value of 1.8 (range
120 140 160 1.5-2.0; n = 7). There were no apparent differences in the
response to these cytokines between non-malignant tonsil and
leukaemic B-cell fractions.
Discussion
This study has examined the effect of various protein kinase
C activators and recombinant cytokines on the in vitro rate
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Table V P2m secretion rates by normal tonsil and leukamic B-cells in the presence of the recombinant cytokines a-interferon (rIFN-4),
y-interferon (rIFN-y), interleukins I and 2 (rIL-l, rIL-2) and tissue necrosis factor (rTNF)a
Controlb rIFN-ac rIFN-yc rIL-lc rIL-2c rTNP rIFN-y/rTNF"
Normal tonsils
I 14.1 21.2 (1.5) 24.0 (1.7) 19.7 (1.4) 30.7 (2.1) 16.9 (1.2 25.4 (1.8)
II 14.6 23.4 (1.6) 23.4 (1.6) 23.4 (1.6) 14.6 (1.0) 17.5 (1.2) 21.9 (1.5)
IV 10.8 19.4 (1.8) 18.4 (1.7) 18.4 (1.7) 18.4 (1.7) 21.6 (2.0) 13.0 (1.2)
B-cell malignancies
CLL (SE) 6.9 n.t. 15.2 (2.2) n.t. 11.0 (1.6) 6.9 (1.0) n.t.
CLL-Pro (EP) 15.5 n.t. 37.2 (2.4) n.t. 15.5 (1.0) 18.6 (1.2) n.t.
CLL-Pro (PR) 7.2 n.t. 23.0 (3.2 n.t. 11.5 (1.6) 7.9 (1.1) n.t.
CLL-Pro (MP) 18.3 23.8 (1.3) 25.6 (1.4) 16.5 (0.9) 29.3 (1.6) 22.0 (1.2) 32.9 (1.8)
CLL-Pro (KH) 23.1 34.6 (1.5) 41.6 (1.8) 25.4 (1.1) 52.9 (2.3) 25.4 (1.1) 46.2 (2.0)
NHL (RT) 37.8 n.t. 56.7 (1.5) n.t. n.t. 34.0 (0.9) 68.0 (1.8)
PLL (KT) 25.8 36.1 (1.4) 41.3 (1.6) 28.4 (1.1) 38.7 (1.5) 25.8 (1.0) n.t.
HCLv (LM) 29.1 n.t. 49.5 (1.7) n.t. 43.7 (1.5) 29.1 (1.0) 49.5 (1.7)
'Results are shown as absolute P2m production rates (ngml-' (106cells)' day-) in the presence or absence (control) of cytokines.
Production rate ratios, relative to the control (spontaneous) value, are shown in parentheses. bControl value indicates spontaneous P2m
production obtained in the absence of cytokines. cCytokine concentrations as given in Materials and methods. dTwo cytokines used in
combination.
ofP2m production by tonsil and leukaemic B-cells. The spon-
taneous (control) P2m production rates for the tonsil B-cell
fractions were broadly similar to those observed for the
'early' B-cell malignancies (B-CLL and CLL-Pro) whereas
considerably higher unstimulated P2m production rates were
found in all three 'late' B-cell proliferations (B-NHL, B-PLL
and HCL-v). This appears contradictory as tonsil B-cells,
despite their heterogeneity, show a more mature immuno-
logical membrane phenotype than B-CLL/CLL-Pro cells
(Jones et al., 1989) and, in terms of differentiation, are closer
in ontogeny to malignant B-cell expansions such as B-NHL,
B-PLL and HCL-v.
Of the activators and cytokines examined, TPA was the
most potent stimulator of P2m production in both tonsil and
leukaemic B-cells. Compared to the control cultures, TPA
increased P2m production in the 11 non-malignant and
leukaemic cases studied by a mean factor of 3.5. In addition,
with the exception of one CLL-Pro case (PR) which showed
a marked increase in TPA-induced P2m production and was
the only B-cell malignancy examined with evidence of a
proliferative component (12% nuclear Ki-67+), there were no
significant differences in the levels of increased production
between tonsil and leukaemic B-cells. However, different re-
sponses were apparent for tonsil and leukaemic B-cells when
TPA was used in combination with the calcium mobilising
ionophore A23187. An enhancement of TPA-induced P2m
production occurred in tonsil B-cells, whereas A23187
appeared to exert a suppressive effect on TPA-induced pro-
duction in most of the B-cell malignancies. When used singly,
A23187 failed to enhance P2m production much above con-
trol levels in three of four cases of B-cell malignancy, but
induced a modest increase in production rate for all four
tonsil B-cell cultures. Although we are not aware of the
significance of these different responses between 'normal' and
leukaemic B-cells, a potential consideration is that the former
become activated and proliferate in the presence of TPA
whereas the latter are induced to differentiate with little or no
proliferation (Bartoglio, 1983; Drexler et al., 1988). However,
the one case included in this study with evidence of 'low
level' proliferation (case PR) showed response patterns to the
stimulus of A23187 and TPA/A23187 which were more
similar to the other (non-proliferating) leukaemic B-cell cases
than to tonsil B-cells. The ratio of TPA-induced P2m produc-
tion to spontaneous P2m production was particularly striking
in this case, but whether this finding is a reflection of the
proliferation process is not known.
A previous study of leukaemic B-cells in 22 cases of B-
CLL (Simonsson et al., 1986) showed that the mean spon-
taneous in vitro P2m production rate in 12 patients with
progressive disease (NCI committee criteria for CLL) was
0.07 (s.d. ± 0.05) mg 1' from 5 x 106 cells in 24 h, compared
with 0.02 (0.01) mg 1-' for 10 patients with non-progressive
disease. These values correspond to 140 (s.d. ± 100) and 40
(s.d. ± 20) ngml-' (106cells)-' day-' respectively. In a
separate study by the same group (Totterman et al., 1986),
the TPA-treated (1.6 x 10-7 M) B-CLL cells from 15 cases of
'active disease' produced the equivalent of 160 (s.d. ± 60)
ngml' (106cells)-'day-', compared with a control rate of
73.3 (s.d. ± 30) ngml-' (106 cells)-' day-', whereas 17 cases
of 'inactive disease' produced 43.3 (s.d. ± 30) and 26.7
(s.d. ± 20) ng ml' (106 cells)-' day-', respectively. Despite
methodological differences between the two studies, these
values are in general agreement with our own, although their
study did not distinguish between CLL and the clinically
more aggressive CLL-Pro variant.
No apparent differences in the response of tonsil and
leukaemic B-cells to the immunoregulatory agents IL-1, IL-2,
IFN-y, IFN-a and TNF were seen. The stimulatory capacity
of IL-2 was found to be greater than IL-1, and IFN-y was
greater than IFN-a but in almost no case was the stimulation
of P2m production as extensive as that produced by TPA or
bryostatin-1. Although TNF and IFN-'y have been reported
to act synergistically in enhancing MHC class I (and
therefore P2m) expression (Pfizenmaier et al., 1987), this was
clearly not the case in terms ofP2m export, as the production
rate by IFN-y/TNF-stimulated cells was not apparently
greater than that of cells stimulated by IFN-y alone.
The precise significance of enhanced P2m production with
stimulation has not been established, but it may simply
reflect the degree of differentiation thus induced. It is
generally accepted that the stage of B-cell differentiation is
broadly reflected by the IgM secretion rate. However, it is
apparent from this study that, despite the slight (P <0.05)
correlation between the spontaneous P2m and IgM secretion
rates, that the degree of leukaemic cell differentiation appears
more closely correlated with the P2m production rate.
Moreover, the suppression in TPA-induced P2m production
rates observed when TPA and A23187 were used in combina-
tion was not apparent for IgM secretion rates. The measure-
ment of P2m production rates could therefore be of poten-
tially more value than IgM production rates in assessing the
response of leukaemic cells to biomodulating agents. Hence,
using P2m production rate as an index of response, the
recominant cytokines IL-1, IL-2, IFN-y, IFN-a and TNF
were considerably less potent than TPA (with or without
calcium ionophore), which is at least consistent with previous
observations (Drexler et al., 1988; Drexler, unpublished
observations) showing that such stimuli are not at all, or only
weakly, efficient in inducing B-CLL differentiation.
Alternatively, the level of spontaneous P2m production
might represent a marker for the degree of activation of a
B-cell. It is noteworthy that in 8/11 of the leukaemic popula-
tions examined, the control P2m production rates were higher
than those of the tonsil B-cell fractions. Based on their680 R.A. JONES et al.
cytomorphological and surface antigen (SIg) features, B-CLL
cells were originally considered as the malignant counterparts
of small resting B-cells (Robert et al., 1986). However, recent
functional studies suggested that B-CLL cells are arrested in
an 'activated' state (Beiske et al., 1988) that is reflected by
the expression of one or more activation-associated antigens
such as FMC7, UCHB1, CD25, B5 or B7 (Table III). Fur-
thermore, the morphology of B-PLL cells and B-CLL cells in
'prolymphocytoid transformation' (CLL-Pro) resembles that
described for activated normal B-cells (Melo et al., 1986).
Thus, viewed in these terms, our data on spontaneous P2m
secretion supports the contention that the leukaemic cells
from B-CLL, CLL-Pro and, in particular, B-PLL represent
cells at an activated stage of B-cell differentiation.
We also analysed the effects of the new protein kinase C
stimulator bryostatin-1. In contrast to phorbol esters,
bryostatin-1 lacks tumour-promoting activity and even has
anti-neoplastic properties (Blumberg, 1988). The naturally
occurring bryostatin-1, a macrocyclic lactone isolated from
the marine bryozoan Bugula neritina, binds to protein kinase
C and, like TPA, stimulates its activity. However, bryostatin-
1 induces only some of the responses obtained with phorbol
esters and may even block TPA-mediated responses in some
experimental situations (Drexler et al., 1989). The 'weaker'
effects of bryostatin-l on some parameters might be
explained by a more transient action for bryostatins
associated with accelerated breakdown of protein kinase C.
In our study, bryostatin-1 was effective in inducing P2m
production, particularly in combination with A23187, but the
levels of P2m induced by bryostatin-l used singly were
significantly lower than those found in cultures exposed to
TPA. In tonsil B-cells, the combination of bryostatin-1 and
A23187 was not as stimulatory for P2m production as was
the TPA/A23187 combination, whereas for leukaemic B-cells,
the two combinations had approximately equal potency. This
was probably an indirect result, in these particular cases, of
the suppressive effect on TPA-induced P2m production by
A23187.
Finally, this study supports previous evidence that the
signal transduction pathway distal to protein kinase C is
intact in B-CLL and related leukaemic cells and can be
stimulated effectively by protein kinase C agonists such as
TPA or bryostatin-l (Drexler et al., 1988, 1989).
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